Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

NeuSpera

NeuSpera
2013 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$26M LATEST DEAL AMOUNT
6 INVESTORS
Description

Developer of miniaturized injectable neuromodulation devices designed to deliver a liberating alternative treatment. The company's miniaturized injectable neuromodulation devices include implantable neuromodulation devices that use mid-field powering techniques which seek to improve the lives of patients suffering from chronic illness by judging the symptoms, enabling patients to get advanced neuromodulation therapy for their disease, to recover faster.

Formerly Known As
Vivonda Medical
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Primary Office
  • 2841 Junction Avenue
  • Suite 101
  • San Jose, CA 95134
  • United States

+1 (888) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore NeuSpera’s full profile, request a free trial.

NeuSpera Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 24-Jan-2018 $26M 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series A) 26-Apr-2016 00.000 00.00 000.00 Completed Startup
1. Angel (individual) $1M $1M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

NeuSpera Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

NeuSpera Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioWave Venture Capital-Backed Norwalk, CT 00 00.000 00000000000 00.000
000000000 Corporation Berlin, Germany
000000 Formerly VC-backed Rydalmere, Australia 00 000.00 000000000 000.00
000000000 Venture Capital-Backed Netanya, Israel 00 0000 00000000000 0000
000000 0000000 Venture Capital-Backed Willoughby Hills, OH 00 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

NeuSpera Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
6 Dimensions Capital Venture Capital Minority 000 0000 000000 0
Alumni Ventures Group Venture Capital Minority 000 0000 000000 0
Delta Capital Growth/Expansion Minority 000 0000 000000 0
Purple Arch Ventures Venture Capital Minority 000 0000 000000 0
Action Potential Venture Capital Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

NeuSpera Executive Team (5)

Name Title Board
Seat
Contact
Info
Milton Morris Ph.D President, Board Member & Chief Executive Officer
Alexander Yeh Ph.D Chief Technology Officer, Founder and Director
Tim Fayram Vice President of Clinical & Regulatory Affairs
Stephen Schellenberg Vice President, Operations
Tim Ciciarelli Vice President, Research & Development

NeuSpera Board Members (5)

Name Representing Role Since Contact
Info
Ching Zhu Ph.D 6 Dimensions Capital Board Member 000 0000
Imran Eba Action Potential Venture Capital Board Member 000 0000
Juan-Pablo Mas Action Potential Venture Capital Board Observer 000 0000
Milton Morris Ph.D NeuSpera President, Board Member & Chief Executive Officer 000 0000
Mudit Jain Ph.D Self Board Member 000 0000